Publications and communications of Pierre FOIDART

Foidart, P. (12 May 2023). The Whole genome doubling leads to an immune escape in TNBC [Paper presentation]. Molecular and cellular oncology -Dana-Farber conference, Cambridge, United States.

Alečković, M., Cristea, S., Gil Del Alcazar, C. R., Yan, P., Ding, L., Krop, E. D., Harper, N. W., Rojas Jimenez, E., Lu, D., Gulvady, A. C., Foidart, P., Seehawer, M., Diciaccio, B., Murphy, K. C., Pyrdol, J., Anand, J., Garza, K., Wucherpfennig, K. W., Tamimi, R. M., ... Polyak, K. (07 December 2022). Breast cancer prevention by short-term inhibition of TGFβ signaling. Nature Communications, 13 (1), 7558. doi:10.1038/s41467-022-35043-5

Hamdi, J., FOIDART, P., & Ali, D. (2021). Mediastinal malposition of a catheter enhanced by an unusual stenosis of the left brachiocephalic vein due to a former long-term haemodialysis catheter. Journal of Medical Case Reports and Case Serie.

Coussy, F., El-Botty, R., Château-Joubert, S., Dahmani, A., Montaudon, E., Leboucher, S., Morisset, L., Painsec, P., Sourd, L., Huguet, L., Nemati, F., Servely, J.-L., Larcher, T., Vacher, S., Briaux, A., Reyes, C., La Rosa, P., Lucotte, G., Popova, T., ... Marangoni, E. (2020). BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science Translational Medicine, 12 (532). doi:10.1126/scitranslmed.aax2625

Foidart, P. (28 January 2019). Novel combination of target therapies in TNBC based on definition of biomarkers [Paper presentation]. Séminaire des chercheurs Télévie 2019.

Yip, C., FOIDART, P., Noël, A., & Sounni, N. E. (16 January 2019). MT4-MMP: The GPI-Anchored Membrane-Type Matrix Metalloprotease with Multiple Functions in Diseases. International Journal of Molecular Sciences, 20 (2). doi:10.3390/ijms20020354

Delmotte, V., Foidart, P., DE VOEGHT, A., LEJEUNE, M., & Delwaide, J. (2019). Diagnostic différentiel de l’anémie dans la cirrhose éthylique. Revue Médicale de Liège, 74 (10), 527-534.

FOIDART, P., Yip, C., Radermacher, J., Blacher, S., Lienard, M., MONTERORUIZ, L., Maquoi, E., Montaudon, E., Chateau-Joubert, S., COLLIGNON, J., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E.* , & JERUSALEM, G.*. (2019). Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-18-1880
* These authors have contributed equally to this work.

FOIDART, P. (02 July 2018). “MT4-MMP, EGFR and Rb expressions are predictive biomarkers of response to Erlotinib-Palbociclib combination in TNBC” [Poster presentation]. 25ème Congrès de l'EARC (Association européenne de recherche sur le cancer), Amsterdam, Netherlands.

FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Coibion, M., Jossa, V., Marangoni, E., Noël, A., Sounni, N. E., & JERUSALEM, G. (24 February 2018). MT4-MMP, EGFR and RB expressions are predictive biomarkers of response to Erlotinib-Palbociclib combination in TNBC [Paper presentation]. Belgian Society of Medical Oncology: annual meeting, Ostende, Belgium.

FOIDART, P., Yip, C., Radermacher, J., MONTERORUIZ, L., Marangoni, E., Noël, A., Sounni, N. E., JERUSALEM, G., Coibion, M., Jossa, V., & BLACHER, S. (27 January 2018). Expression of MT4-MMP, EGFR and Rb in triple negative breast cancers strongly sensitizes tumors to Erlotinib and Palbociclib combination therapy [Paper presentation]. Belgian Association for Cancer Research : Annual Meeting, Liège, Belgium.

Marangoni, E., Laurent, C., Coussy, F., El Botty, R., Chateau-Joubert, S., Servely, J.-L., de Plater, L., Assayag, F., Dahmani, A., Montaudon, E., Nemati, F., Fleury, J., Vacher, S., Gentien, D., Rapinat, A., Foidart, P., Sounni, N. E., Noël, A., Salomon, A., ... Reyal, F. (2018). Capecitabine efficacy is correlated with TYMP and RB expression in PDX established from triple-negative breast cancers. Clinical Cancer Research. doi:10.1158/1078-0432.CCR-17-3490

Yip, C., Foidart, P., Somja, J., Truong, A., Lienard, M., Feyereisen, E., SCHROEDER, H., GOFFLOT, S., Donneau, A.-F., COLLIGNON, J., Delvenne, P., Sounni, N. E., Jerusalem, G., & Noël, A. (2017). MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. British Journal of Cancer. doi:10.1038/bjc.2017.23

Yip, C., FOIDART, P., SOMJA, J., Truong, A., COLLIGNON, J., DELVENNE, P., Sounni, N. E., JERUSALEM, G., & Noël, A. (03 December 2015). MT4-MMP, a potential prognostic factor in triple negative breast cancer [Paper presentation]. Séminaire des chercheurs Télévie 2016, Gembloux, Belgium.

Yip, C., FOIDART, P., SOMJA, J., Truong, A., COLLIGNON, J., DELVENNE, P., Sounni, N. E., JERUSALEM, G., & Noël, A. (September 2015). MT4-MMP, a potential therapeutic target in triple negative breast cancer [Poster presentation]. 2nd international society of cancer metabolism meeting - METABOLISM and MICROENVIRONMENT in CANCER PLASTICITY, Venise, Italy.